Validation Review. In the event OIG has reason to believe that: (a) Good Shepherd’s Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). Good Shepherd shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Good Shepherd’s final Annual Report shall be initiated no later than one year after Good Shepherd’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Good Shepherd of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Good Shepherd may request a meeting with OIG to: (a) discuss the results of any Claims Review submissions or findings; (b) present any additional information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review; and/or (c) propose alternatives to the proposed Validation Review. Good Shepherd agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any Claims Review issues with Good Shepherd prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.
Validation Review. In the event OIG has reason to believe that: (a) Halifax’s Arrangements Review or Unallowable Cost Review fails to conform to the requirements of this CIA; or (b) the Legal IRO’s findings or Arrangements Review or Unallowable Cost Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Arrangements Review or Unallowable Cost Review complied with the requirements of the CIA and/or the findings or Arrangements Review or Unallowable Cost Review results are inaccurate (Validation Review). Halifax shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Halifax’s final Annual Report shall be initiated no later than one year after Halifax’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Halifax of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Halifax may request a meeting with OIG to: (a) discuss the results of any Arrangements Review or Unallowable Cost Review submissions or findings; (b) present any additional information to clarify the results of the Arrangements Review or Unallowable Cost Review or to correct the inaccuracy of the Arrangements Review or Unallowable Cost Review; and/or (c) propose alternatives to the proposed Validation Review. Halifax agrees to provide any additional information as may be requested by OIG under this Section III.E.5 in an expedited manner. OIG will attempt in good faith to resolve any Arrangements Review or Unallowable Cost Review issues with Halifax prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.
Validation Review. In the event OIG has reason to believe that: (a) any of Novartis’ IRO Reviews fail to conform to the requirements of this CIA; or (b) the IRO’s findings or Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the applicable IRO Review complied with the requirements of the CIA and/or the findings or Review results are inaccurate (Validation Review). Novartis shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Novartis’ final Annual Report shall be initiated no later than one year after Novartis’ final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Novartis of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Novartis may request a meeting with OIG to: (a) discuss the results of any IRO Review submissions or findings; (b) present any additional information to clarify the results of the IRO Review or to correct the inaccuracy of the IRO Review; and/or (c) propose alternatives to the proposed Validation Review. Novartis agrees to provide any additional information as may be requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith to resolve any IRO Review issues with Novartis prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.
Validation Review. In the event OIG has reason to believe that: (a) any of the IRO Reviews fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Review in question complied with the requirements of the CIA and/or the findings or Review results are inaccurate (Validation Review). Jazz shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of Reports submitted as part of Jazz’s final Annual Report shall be initiated no later than one year after Jazz’s final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Jazz of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, Jazz may request a meeting with OIG to: (a) discuss the results of any Review submissions or findings; (b) present any additional information to clarify the results of the Review in question or to correct the inaccuracy of the Review; and/or (c) propose alternatives to the proposed Validation Review. Jazz agrees to provide any additional information as may be requested by OIG under this Section in an expedited manner. OIG will attempt in good faith to resolve any IRO Review issues with Jazz prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.
Validation Review. In the event HHS has reason to believe that: (a) the Monitor reviews or reports fail to conform to the requirements of this CAP; or (b) the Monitor report results are inaccurate, HHS may, at its sole discretion, conduct its own review to determine whether the Monitor reviews or reports complied with the requirements of the CAP are inaccurate (“Validation Review”). Prior to initiating a Validation Review, HHS shall notify UCLAHS of its intent to do so and provide a written explanation of why HHS believes such a review is necessary. To resolve any concerns raised by HHS, UCLAHS may request a meeting with HHS to discuss the results of any Monitor review reports; present any additional or relevant information to clarify the results of the Monitor review to correct the inaccuracy of the Monitor review and/or report; and/or propose alternatives to the proposed Validation Review. UCLAHS shall provide any additional information as may be requested by HHS under this section in an expedited manner. HHS will attempt in good faith to resolve any Monitor review concerns with UCLAHS prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of HHS.
Validation Review. In the event OIG has reason to believe that: (a) any Arrangements Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Arrangements Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Arrangements Review complied with the requirements of the CIA and/or the findings or Arrangements Review results are inaccurate (Validation Review). Xxxxx shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of an Arrangements Review submitted as part of Xxxxx’x final Annual Report shall be initiated no later than one year after Xxxxx’x final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify Xxxxx in writing of its intent to do so and provide an explanation of the reasons OIG has determined a Validation Review is necessary. Xxxxx shall have 30 days following the date of the OIG’s written notice to submit a written response to OIG that includes any additional or relevant information to clarify the results of the Arrangements Review or to correct the inaccuracy of the Arrangements Review and/or propose alternatives to the proposed Validation Review. The final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.
Validation Review. In the event OIG has reason to believe that: (a) any of the IRO Reviews fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the applicable IRO Review complied with the requirements of the CIA and/or the findings or Review results are inaccurate (Validation Review). J&J shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents. Any Validation Review of reports submitted as part of J&J’s final Annual Report shall be initiated no later than one year after J&J’s final submission (as described in Section II.B) is received by OIG. Prior to initiating a Validation Review, OIG shall notify J&J of its intent to do so and provide a written explanation of why OIG believes such a review is necessary. To resolve any concerns raised by OIG, J&J may request a meeting with OIG to: (a) discuss the results of any IRO Review submissions or findings; (b) present any additional information to clarify the results of the IRO Review or to correct the inaccuracy of the IRO Review; and/or (c) propose alternatives to the proposed Validation Review. J&J agrees to provide any additional information as may be requested by OIG under this Section III.E.3 in an expedited manner. OIG will attempt in good faith to resolve any IRO Review issues with J&J prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.
Validation Review. In the event OIG has reason to believe that:
(a) any Claims Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or Claims Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to determine whether the Claims Review complied with the requirements of the CIA and/or the findings or Claims Review results are inaccurate (Validation Review). The Providers shall pay for the reasonable cost of any such review performed by OIG or any of its designated agents so long as it is initiated within one year after the Providers’ final submission (as described in Section II) is received by OIG. Prior to initiating a Validation Review, OIG shall notify the Providers in writing of its intent to conduct a Validation Review and the reasons OIG has determined a Validation Review is necessary. The Providers shall have up to 30 days following the date of the OIG’s written notice to submit a written response to OIG that includes any additional or relevant information to clarify the results of the Claims Review or to correct the inaccuracy of the Claims Review and/or to propose alternatives to the proposed Validation Review. OIG will attempt in good faith to resolve any Claims Review issues with the Providers prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of OIG.
Validation Review. In the event HHS, in its discretion, determines or has reason to believe that: (a) one or more Assessor Reports fail to conform to the requirements of this CAP; or (b) one or more Assessor Reports are factually inaccurate or otherwise improper or incomplete, HHS may, in its sole discretion, conduct its own review to determine whether the Assessor Report(s) comply with the requirements of this CAP and/or are factually inaccurate, incorrect or otherwise improper ("Validation Review"). Prior to initiating a Validation Review, HHS shall notify the Contact Person of its intent to do so and provide a written explanation of why HHS believes such a review is necessary. To resolve any concerns raised by HHS, the Contact Person may request a meeting with HHS to discuss the results of any Assessor review submissions or findings; present any additional or relevant information to clarify the results of the Assessor review to correct the inaccuracy of the Assessor review; and/or propose alternatives to the proposed Validation Review. The Contact Person shall provide any additional information as may be requested by HHS under this section in an expedited manner. HHS will attempt in good faith to resolve any Assessor review concerns with the Contact Person prior to conducting a Validation Review. However, the final determination as to whether or not to proceed with a Validation Review shall be made at the sole discretion of HHS.
Validation Review. In the event HHS has reason to believe that: (a) the Monitor reviews or reports fail to conform to the requirements of this CAP; or (b) the Monitor report results are inaccurate, HHS may, at its sole discretion, conduct its own review to determine whether the Monitor reviews or reports complied with the requirements of the CAP and/or are inaccurate (“Validation Review”).
